These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33819508)

  • 21. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study.
    Khinchi MS; Poulsen LK; Carat F; André C; Hansen AB; Malling HJ
    Allergy; 2004 Jan; 59(1):45-53. PubMed ID: 14674933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapy.
    Baron-Bodo V; Horiot S; Lautrette A; Chabre H; Drucbert AS; Danzé PM; Sénéchal H; Peltre G; Galvain S; Zeldin RK; Horak F; Moingeon P
    Clin Exp Allergy; 2013 Dec; 43(12):1362-73. PubMed ID: 24261946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy.
    Shamji MH; Ljørring C; Francis JN; Calderon MA; Larché M; Kimber I; Frew AJ; Ipsen H; Lund K; Würtzen PA; Durham SR
    Allergy; 2012 Feb; 67(2):217-26. PubMed ID: 22077562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit.
    Ellis AK; Tenn MW; Steacy LM; Adams DE; Day AG; Walker TJ; Nolte H
    Ann Allergy Asthma Immunol; 2018 May; 120(5):495-503.e2. PubMed ID: 29432967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy.
    Kiel MA; Röder E; Gerth van Wijk R; Al MJ; Hop WC; Rutten-van Mölken MP
    J Allergy Clin Immunol; 2013 Aug; 132(2):353-60.e2. PubMed ID: 23651609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy is allergen-specific: a double-blind trial of mite or timothy extract in mite and grass dual-allergic patients.
    Dreborg S; Lee TH; Kay AB; Durham SR
    Int Arch Allergy Immunol; 2012; 158(1):63-70. PubMed ID: 22212720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.
    Scadding GW; Calderon MA; Shamji MH; Eifan AO; Penagos M; Dumitru F; Sever ML; Bahnson HT; Lawson K; Harris KM; Plough AG; Panza JL; Qin T; Lim N; Tchao NK; Togias A; Durham SR;
    JAMA; 2017 Feb; 317(6):615-625. PubMed ID: 28196255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sublingual immunotherapy alters salivary IgA and systemic immune mediators in timothy allergic children.
    Huoman J; Papapavlou G; Pap A; Alm J; Nilsson LJ; Jenmalm MC
    Pediatr Allergy Immunol; 2019 Aug; 30(5):522-530. PubMed ID: 30803044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract.
    Amar SM; Harbeck RJ; Sills M; Silveira LJ; O'Brien H; Nelson HS
    J Allergy Clin Immunol; 2009 Jul; 124(1):150-156.e1-5. PubMed ID: 19523672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study.
    Yukselen A; Kendirli SG; Yilmaz M; Altintas DU; Karakoc GB
    Int Arch Allergy Immunol; 2012; 157(3):288-98. PubMed ID: 22041501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allergens. Heterogeneity of molecular sensitization profiles in grass pollen allergy--implications for immunotherapy?
    Darsow U; Brockow K; Pfab F; Jakob T; Petersson CJ; Borres MP; Ring J; Behrendt H; Huss-Marp J
    Clin Exp Allergy; 2014; 44(5):778-86. PubMed ID: 24598010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison.
    Di Bona D; Plaia A; Leto-Barone MS; La Piana S; Di Lorenzo G
    J Allergy Clin Immunol; 2012 Nov; 130(5):1097-1107.e2. PubMed ID: 23021885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
    Klimek L; Schendzielorz P; Pinol R; Pfaar O
    Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost.
    Dranitsaris G; Ellis AK
    J Eval Clin Pract; 2014 Jun; 20(3):225-38. PubMed ID: 24444390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Shorter dosing intervals of sublingual immunotherapy lead to more efficacious treatment in a mouse model of allergic inflammation.
    Rask C; Brimnes J; Lund K
    Scand J Immunol; 2010 Jun; 71(6):403-12. PubMed ID: 20500692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Grass pollen allergoids conjugated with mannan for subcutaneous and sublingual immunotherapy: a dose-finding study.
    Ojeda P; Barjau MC; Subiza J; Moreno A; Ojeda I; Solano E; Alonso A; Caballero R; Del Pozo S; Gómez-Perosanz M; Sánchez-Trincado JL; Benito-Villalvilla C; Angelina A; Soria I; Reche PA; Palomares O; Subiza JL; Casanovas M
    Front Immunol; 2024; 15():1431351. PubMed ID: 38989287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
    Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
    J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-response relationship of a new Timothy grass pollen allergoid in comparison with a 6-grass pollen allergoid.
    Pfaar O; Hohlfeld JM; Al-Kadah B; Hauswald B; Homey B; Hunzelmann N; Schliemann S; Velling P; Worm M; Klimek L
    Clin Exp Allergy; 2017 Nov; 47(11):1445-1455. PubMed ID: 28696503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of immunoglobulin E responses in Balb/c mice against the major allergens of timothy grass (Phleum pratense) pollen.
    Seitzer U; Bussler H; Kullmann B; Petersen A; Becker WM; Ahmed J
    Clin Exp Allergy; 2003 May; 33(5):669-75. PubMed ID: 12752597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.